AIDS.GOV | SERVICE LOCATOR | SEARCH

BLOG.AIDS.GOV

MENU

Viral Hepatitis

Silence is Deadly: Combating the Epidemic of Viral Hepatitis

mccance-katz

Silence=Death. That phrase was used by the advocacy group ACT UP to end the silence about the AIDS crisis in the United States. This is no less true for the issue of viral hepatitis, which claims the lives of 12,000-18,000 Americans each year. Our inactivity can fuel the spread of viral hepatitis—viruses which are largely…

Primary Care Providers: Improve Care for Patients with Viral Hepatitis with ACT-First, a Free Online CME Course

garciatsaog

Regular readers of this blog probably know that the Centers for Disease Control and Prevention (CDC) recommends hepatitis C (HCV) screening for everyone in the demographic group in the U.S. that is most likely to be infected—people born between 1945 and 1965. In addition, the U.S. Preventive Services Task Force (USPSTF) last year upgraded its…

Advancing the Viral Hepatitis Action Plan: Checking-In with Federal and Community Leaders

VHIG Oct 2014-035

On Tuesday, 10/14/14, the cross-government working group supporting and monitoring the implementation of the updated Viral Hepatitis Action Plan—the Viral Hepatitis Implementation Group or “VHIG”—met in Washington, DC to share updates on 2014 accomplishments and plans for the coming year. Some of the highlights included: Promising preliminary data from HRSA’s Bureau of Primary Health Care…

FDA approves first combination pill to treat hepatitis C

FDA

The U.S. Food and Drug Administration today approved Harvoni (ledipasvir and sofosbuvir) to treat chronic hepatitis C virus (HCV) genotype 1 infection. Harvoni is the first combination pill approved to treat chronic HCV genotype 1 infection. It is also the first approved regimen that does not require administration with interferon or ribavirin, two FDA-approved drugs…

USCA 2014: Viral Hepatitis in the Spotlight for the First Time

Corinna Dan

Viral hepatitis has long been a concern of organizations working in the HIV/AIDS field because of high rates of co-infection. It is estimated that 10% of people living with HIV are co-infected with hepatitis B and 25% are co-infected with hepatitis C, though certain groups, like people who inject drugs, have even higher rates of…

Corinna Dan Reflects on Her Commitment to Fighting Viral Hepatitis and Introduces Viral Hepatitis Action Plan

Corinna Dan

Many of our colleagues in the HIV/AIDS and viral hepatitis fields have both personal and professional commitments to their work, formed by diverse life experiences that continue to inspire them. Recently, we visited with our colleague Ms. Corinna Dan, R.N., M.P.H., who serves as Viral Hepatitis Policy Advisor in the HHS Office of HIV/AIDS and…

National Recovery Month: An Opportunity to Integrate Behavioral Health and Hepatitis C Prevention

NRM_2014_English_logo

Every year in September, we recognize National Recovery Month. Now in its 25th year, Recovery Month highlights how prevention and treatment of and recovery from mental and substance use disorders benefit individuals and our communities. This year’s theme is “Join the Voices for Recovery: Speak Up, Reach Out.” “Recovery Month reminds us that our year-round…

CDC Shares Resources on the Risks of Healthcare-associated Infections from Drug Diversion

drug diversion

Quality health care is safe health care; neither patients nor providers should be at risk for acquiring HBV, HCV, or other bloodborne infections during health care encounters. Viral hepatitis stakeholders recognize that such health care-associated infections are an important public health and patient safety issue and are committed to better understanding the causes and further…